Ligand ID: ZPC


Drugbank ID:
DB00402
(Eszopiclone)
DB01198
(Zopiclone)


Indication:
For the treatment of insomnia;For the short-term treatment of insomnia.

Get human targets for ZPC in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'ZPC'

Click here for results that match SARS-Cov-2 / COVID-19 structures only
Click here for results that match SARS-related structures only


1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		1q2w 3C-LIKE PROTEASE
(SARSr-CoV)		4 / 6
GLU B 288
ILE B 286
PHE B 291
VAL B 114
1.65A21.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		1q2w 3C-LIKE PROTEASE
(SARSr-CoV)		4 / 7
GLU B 288
GLU B 290
PHE B 291
VAL B 125
1.52A21.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2a5k 3C-LIKE PEPTIDASE
(SARSr-CoV)		4 / 7
GLU B 288
GLU B 290
PHE B 291
VAL B 125
1.37A20.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2ahm REPLICASE
POLYPROTEIN 1AB,
HEAVY CHAIN
REPLICASE
POLYPROTEIN 1AB,
LIGHT CHAIN
(SARSr-CoV)		4 / 8
VAL C  38
ARG F  85
ASN C  42
GLU B  28
1.50A13.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2ahm REPLICASE
POLYPROTEIN 1AB,
HEAVY CHAIN
REPLICASE
POLYPROTEIN 1AB,
LIGHT CHAIN
(SARSr-CoV)		4 / 7
VAL C  38
ARG F  85
ASN C  42
GLU B  28
1.49A13.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2ajf SPIKE PROTEIN
(SARSr-CoV)		4 / 6
GLU E 502
PHE E 501
TYR E 383
VAL E 328
1.55A20.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2ajf ACE2
(Homo
sapiens)		4 / 7
VAL B  93
ILE B  88
ASN B  90
GLU B 564
1.29A16.97
None
None
NAG  B1090 (-1.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2ajf ACE2
(Homo
sapiens)		4 / 8
VAL B  93
ILE B  88
ASN B  90
GLU B 564
1.30A16.97
None
None
NAG  B1090 (-1.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2alv REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.44A20.35
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2amq 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.52A21.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2cjr NUCLEOCAPSID PROTEIN
(SARS-COV
TW1)		4 / 7
ILE C 293
HIS C 301
VAL C 351
PHE C 287
1.45A14.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2d2d 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 6
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.57A21.61
None
None
ENB  A 307 (-4.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_B_ZPCB1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2fe8 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
TYR B 269
ILE C 223
TYR B 265
HIS B 273
VAL C 188
1.80A20.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2ga6 ORF1A POLYPROTEIN
(SARSr-CoV)		4 / 7
GLU H  66
PHE H  68
HIS G  48
VAL K  21
1.34A17.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2ga6 ORF1A POLYPROTEIN
(SARSr-CoV)		4 / 6
GLU H  66
PHE H  68
HIS G  48
VAL K  21
1.39A17.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2gdt NSP1 (EC 3.4.22.-)
P65 HOMOLOG
LEADER PROTEIN
(SARSr)		4 / 6
GLU A  30
HIS A  99
VAL A  43
PHE A  20
1.31A17.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2gib NUCLEOCAPSID PROTEIN
(SARSr-CoV)		4 / 7
ILE A 293
HIS A 301
VAL A 351
PHE A 287
1.52A14.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2gri NSP3
(SARSr)		4 / 8
PHE A  54
TYR A  43
VAL A  22
GLU A  53
1.42A14.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2h85 PUTATIVE ORF1AB
POLYPROTEIN
(SARSr-CoV)		4 / 7
PHE A 232
TYR A 230
VAL A 303
GLU A 233
1.45A21.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2kaf NSP3
(SARSr-CoV)		4 / 7
GLU A  27
TYR A  41
HIS A  42
VAL A  56
1.56A15.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_B_ZPCB1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 12
ILE B  85
ASN B  62
GLU B 145
VAL B  77
PHE B 176
1.71A21.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		4 / 6
ILE C 222
TYR C 237
HIS C 234
VAL C 294
1.63A21.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		4 / 7
ILE D 222
TYR D 237
HIS D 234
PHE D 213
1.45A21.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2q6g REPLICASE
POLYPROTEIN 1AB
(SARS-COV
BJ01)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.49A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2qcy 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 7
ILE A 286
GLU A 288
HIS A 172
PHE A 291
1.68A19.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2qiq REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.39A20.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		4 / 7
PHE C 232
TYR C 230
VAL C 303
GLU C 233
1.48A20.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		4 / 7
ILE B 222
TYR B 237
VAL B 294
PHE B 213
1.65A20.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 12
PHE B  55
VAL B   9
ILE A 269
GLU B  91
VAL B  40
1.30A20.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_F_ZPCF1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2wct NSP3
(SARSr-CoV)		5 / 12
GLU B 402
HIS D 613
TYR D 610
ARG A 473
ASN D 616
1.79A18.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2wct NSP3
(SARSr-CoV)		4 / 7
GLU B 402
TYR D 610
VAL D 589
PHE B 406
1.62A18.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		2z3e REPLICASE
POLYPROTEIN 1AB
(PP1AB)
(SARSr-CoV)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.34A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3avz 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 6
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.67A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3bgf F26G19 FAB
(Mus
musculus)		4 / 7
ILE C 106
GLU C 105
TYR C 173
HIS B 166
1.44A20.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3bgf F26G19 FAB
(Mus
musculus)		4 / 7
ILE C 106
GLU C 105
TYR C 173
HIS B 166
1.47A20.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3d0g SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
GLU E 502
PHE E 501
TYR E 383
VAL E 328
1.53A20.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3d0g ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
PHE B 369
VAL B 293
ILE B 291
GLU B 406
HIS B 417
1.54A16.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3d0g SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 6
GLU E 502
PHE E 501
TYR E 383
VAL E 328
1.55A20.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 7
VAL B  93
ILE B  88
ASN B  90
GLU B 564
1.28A16.83
None
None
NDG  B 616 (-2.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3d0h SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 6
GLU E 502
PHE E 501
TYR E 383
VAL E 328
1.63A20.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 8
VAL B  93
ILE B  88
ASN B  90
GLU B 564
1.29A16.83
None
None
NDG  B 616 (-2.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3d0i SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 6
GLU F 502
PHE F 416
TYR F 383
VAL F 420
1.41A20.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3d0i SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
GLU F 502
PHE F 416
TYR F 383
VAL F 420
1.29A20.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3d0i ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 7
GLU A 435
HIS A 417
VAL A 293
PHE A 428
1.64A16.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3ea8 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.41A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_B_ZPCB1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3i6g BETA-2-MICROGLOBULIN
HLA, A-2
(Homo
sapiens)		5 / 12
TYR B  63
ILE B  35
GLU A 232
TYR B  26
VAL B  82
1.61A16.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3i6k HLA, A-2
(Homo
sapiens)		4 / 6
PHE A   8
HIS A   3
VAL A 165
PHE A  33
1.32A22.09
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_B_ZPCB1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3i6l HLA, A-24
NUCLEOPROTEIN
PEPTIDE
(Homo
sapiens;
SARSr-CoV)		5 / 12
TYR D   7
ILE F   7
GLU D  63
TYR D 159
VAL D 152
1.53A21.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3iwm 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 6
ILE D 200
PHE B 291
HIS D 172
VAL D 125
1.62A20.00
None
None
PJE  E   5 ( 4.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3sci SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
GLU E 502
PHE E 416
TYR E 383
VAL E 420
1.42A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3sci SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 6
GLU E 502
PHE E 416
TYR E 383
VAL E 420
1.50A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3sci ACE2
(Homo
sapiens)		5 / 12
PHE B 369
VAL B 293
ILE B 291
GLU B 406
HIS B 417
1.57A16.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_B_ZPCB1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3sci ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 12
PHE F 483
TYR F 491
ILE F 405
GLU B  37
VAL F 337
1.79A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_B_ZPCB1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3sci ACE2
(Homo
sapiens)		5 / 12
TYR A 497
GLU A 495
GLU A 166
GLU A 489
VAL A 506
1.76A16.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3scj ACE2
(Homo
sapiens)		4 / 8
VAL B  93
ILE B  88
ASN B  90
GLU B 564
1.25A16.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3scj ACE2
(Homo
sapiens)		4 / 7
VAL B  93
ILE B  88
ASN B  90
GLU B 564
1.24A16.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3scj ACE2
(Homo
sapiens)		4 / 6
GLU B 430
HIS B 417
VAL B 293
PHE B 428
1.56A16.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_B_ZPCB1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3scj ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 12
PHE F 483
TYR F 491
ILE F 405
GLU B  37
VAL F 337
1.78A19.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3scj ACE2
(Homo
sapiens)		4 / 7
GLU B 435
GLU B 430
HIS B 417
VAL B 293
1.54A16.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3scj SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
GLU E 502
PHE E 416
TYR E 383
VAL E 420
1.43A19.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3sck SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
GLU E 502
PHE E 501
TYR E 383
VAL E 328
1.51A19.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3sck ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
VAL A 581
GLU A 231
ILE A 223
TYR A 454
VAL A 447
1.58A16.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3sck SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 6
GLU F 502
PHE F 501
TYR F 383
VAL F 328
1.61A19.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3scl SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
GLU E 502
PHE E 501
TYR E 383
VAL E 328
1.55A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3scl SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 6
GLU E 502
PHE E 501
TYR E 383
VAL E 328
1.62A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 7
VAL B  93
ILE B  88
ASN B  90
GLU B 564
1.30A16.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 7
GLU B 457
ILE B 513
GLU B 398
TYR B 207
1.67A16.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 8
VAL B  93
ILE B  88
ASN B  90
GLU B 564
1.30A16.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		3sna 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.52A20.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		4ow0 PAPAIN-LIKE PROTEASE
(SARS-COV
Urbani)		4 / 7
ILE B 152
TYR B 113
HIS B 273
VAL A 226
1.56A20.63
None
None
OCS  B 112 ( 3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		4ow0 PAPAIN-LIKE PROTEASE
(SARS-COV
Urbani)		4 / 6
ILE B 152
TYR B 113
HIS B 273
VAL A 226
1.62A20.63
None
None
OCS  B 112 ( 3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		4rna PAPAIN-LIKE PROTEASE
(Human
betacoronavirus
2c
EMC/2012)		4 / 8
TYR A 279
VAL A 116
MET A 153
ILE A 152
1.55A19.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		4wy3 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.28A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5b6o 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 7
GLU B 288
GLU B 290
PHE B 291
VAL B 125
1.37A20.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		4 / 6
GLU B 302
ILE B 298
HIS B  82
VAL B 282
1.61A21.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		4 / 7
GLU B 302
ILE B 298
HIS B  82
VAL B 282
1.60A21.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		4 / 7
GLU B 302
ILE B 298
HIS B  82
VAL B 282
1.54A21.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5c8u GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		4 / 7
PHE B 445
TYR B 447
VAL B 316
ILE B 397
1.50A21.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5c8u GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		4 / 8
PHE B 445
TYR B 447
VAL B 316
ILE B 397
1.50A21.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5e6j REPLICASE
POLYPROTEIN 1AB
UBIQUITIN
(SARSr-CoV;
synthetic
construct)		4 / 6
ILE E  44
PHE E  45
TYR D 208
VAL D 236
1.61A15.38
5MW  E  48 ( 4.1A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5e6j REPLICASE
POLYPROTEIN 1AB
UBIQUITIN
(SARSr-CoV;
synthetic
construct)		4 / 7
ILE E  44
PHE E  45
TYR D 208
VAL D 236
1.56A15.38
5MW  E  48 ( 4.1A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		4 / 8
PHE B 445
TYR B 447
VAL B 316
ILE B 397
1.53A21.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.67A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.71A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.59A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.65A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.66A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5tl6 REPLICASE
POLYPROTEIN 1AB
UBIQUITIN-LIKE
PROTEIN ISG15
(Homo
sapiens;
SARSr-CoV)		4 / 7
GLU D 204
GLU C 132
TYR C 140
VAL C  86
1.66A20.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5tl7 UBIQUITIN-LIKE
PROTEIN ISG15
(Mus
musculus)		5 / 12
PHE C 124
VAL C 146
GLU C 130
GLU C 133
VAL C  96
1.64A13.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5x4r S PROTEIN
(MERS-CoV)		4 / 7
GLU A 252
TYR A 144
HIS A 298
VAL A  86
1.32A24.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5x4r S PROTEIN
(MERS-CoV)		4 / 6
GLU A 252
TYR A 144
HIS A 298
VAL A  86
1.49A24.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5x4r S PROTEIN
(MERS-CoV)		4 / 7
GLU A 252
TYR A 144
HIS A 298
VAL A  86
1.42A24.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_B_ZPCB1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5x4r S PROTEIN
(MERS-CoV)		5 / 12
TYR A 144
ILE A 296
GLU A 252
VAL A 170
PHE A 254
1.61A24.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
VAL B 114
ILE B 125
GLU A 452
GLU A 341
VAL B 196
1.44A14.93
None
None
NAG  B1310 ( 4.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 6
GLU B 801
ILE B 800
PHE B 805
VAL B 933
1.57A14.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 6
PHE A 253
HIS A 181
VAL A  97
PHE A  89
1.30A14.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 8
PHE C 193
ARG B 453
ILE C 226
GLU B 502
1.47A14.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 7
ILE B 219
HIS B 181
VAL B 172
PHE B 168
1.66A14.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 7
PHE A 130
VAL A 102
ARG A 232
ILE A 234
1.44A14.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5x5c S PROTEIN
(MERS-CoV)		4 / 6
PHE B 164
HIS B 298
VAL B  33
PHE B 232
1.44A11.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5x5c S PROTEIN
(MERS-CoV)		4 / 6
ILE A  67
PHE A 327
HIS A 348
VAL A  50
1.58A11.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_B_ZPCB1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5x5c S PROTEIN
(MERS-CoV)		5 / 12
TYR C 144
ILE C 296
GLU C 252
VAL C 170
PHE C 254
1.61A11.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5x5f S PROTEIN
(MERS-CoV)		4 / 8
VAL C1082
ILE C 831
ASN C1079
GLU C1090
1.46A11.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5x5f S PROTEIN
(MERS-CoV)		4 / 7
GLU B 252
TYR B 144
HIS B 298
VAL B  86
1.48A11.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5x5f S PROTEIN
(MERS-CoV)		4 / 7
GLU B 252
TYR B 144
HIS B 298
VAL B  86
1.40A11.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5x5f S PROTEIN
(MERS-CoV)		4 / 7
VAL C1082
ILE C 831
ASN C1079
GLU C1090
1.44A11.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 6
GLU B 801
ILE B 800
PHE B 805
VAL B 933
1.63A14.66
GLU  B 801 ( 0.5A)
ILE  B 800 ( 0.7A)
PHE  B 805 ( 1.3A)
VAL  B 933 ( 0.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
TYR C 252
HIS C  70
VAL C  66
PHE C  89
1.54A14.66
TYR  C 252 ( 1.3A)
HIS  C  70 ( 1.0A)
VAL  C  66 ( 0.6A)
PHE  C  89 ( 1.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
TYR A 195
VAL A 196
ILE A 116
GLU A  45
1.39A14.66
TYR  A 195 ( 1.3A)
VAL  A 196 ( 0.6A)
ILE  A 116 ( 0.6A)
GLU  A  45 ( 0.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
TYR A 195
VAL A 196
ILE A 116
GLU A  45
1.34A14.66
TYR  A 195 ( 1.3A)
VAL  A 196 ( 0.6A)
ILE  A 116 ( 0.6A)
GLU  A  45 ( 0.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5y3e REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		4 / 7
GLU A 180
HIS A 172
VAL A 117
PHE A 128
1.65A20.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5zvm PAN-COV INHIBITORY
PEPTIDE EK1
(synthetic
construct)		4 / 8
PHE b  15
VAL b  13
ILE b  11
ASN b  12
1.24A9.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		5zvm PAN-COV INHIBITORY
PEPTIDE EK1
(synthetic
construct)		4 / 7
PHE b  15
VAL b  13
ILE b  11
ASN b  12
1.29A9.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
GLU A 174
PHE A 238
HIS A  74
VAL A  25
1.40A14.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 6
GLU A 174
PHE A 238
HIS A  74
VAL A  25
1.46A14.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_B_ZPCB1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
TYR C 195
ILE C 228
ASN C 189
GLU A 502
VAL C 114
1.69A14.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
ILE B1096
HIS C1065
VAL C1111
PHE C1103
1.39A14.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
PHE B 168
VAL B 123
ILE B 116
ASN B 118
VAL B 196
1.39A14.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
PHE C 168
VAL C 123
ILE C 116
ASN C 118
1.05A14.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
PHE C 168
VAL C 123
ILE C 116
ASN C 118
1.03A14.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 6
PHE A 253
HIS A 181
VAL A  97
PHE A  89
1.22A14.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 6
GLU A 801
ILE A 800
PHE A 805
VAL A 933
1.53A14.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 8
TYR C 195
VAL C 196
ILE C 116
GLU C  45
1.42A14.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 7
TYR A 195
VAL A 196
ILE A 116
GLU A  45
1.34A14.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 6
PHE A 253
HIS A 181
VAL A  97
PHE A  89
1.51A14.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 7
ILE A  81
TYR A 252
HIS A  70
PHE A  89
1.39A12.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
PHE A1044
VAL A1015
ILE A 800
GLU A 801
VAL A 767
1.57A12.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6cs0 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 6
ILE C  81
PHE C  89
HIS C  70
VAL C 205
1.41A12.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6cs0 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 7
ILE C  81
PHE C  89
HIS C  70
VAL C 205
1.39A12.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_B_ZPCB1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6cs0 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
ASN A 889
GLU A1074
GLU C1074
VAL A 897
PHE C1103
1.46A12.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 8
PHE B  69
TYR B 252
VAL B 254
ILE B  87
1.17A12.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 7
PHE B  69
TYR B 252
VAL B 254
ILE B  87
1.16A12.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6cs2 ACE2
(Homo
sapiens)		4 / 8
TYR D 199
ARG D 192
ASN D 188
GLU D 457
1.41A17.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6cs2 ACE2
(Homo
sapiens)		4 / 7
GLU D 398
ILE D 513
TYR D 217
VAL D 212
1.27A17.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6cs2 ACE2
(Homo
sapiens)		4 / 6
GLU D 398
ILE D 513
TYR D 217
VAL D 212
1.24A17.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6cs2 ACE2
(Homo
sapiens)		4 / 7
TYR D 199
ARG D 192
ASN D 188
GLU D 457
1.44A17.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 6
PHE C 253
HIS C 181
VAL C  97
PHE C  89
1.17A12.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6cs2 ACE2
(Homo
sapiens)		4 / 7
GLU D 398
ILE D 513
TYR D 217
VAL D 212
1.30A17.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6iex MHC CLASS I ANTIGEN
(Homo
sapiens;
SARSr-CoV)		5 / 12
GLU A  63
ILE A  66
GLU C   2
TYR A  99
VAL A 103
1.62A21.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6iex MHC CLASS I ANTIGEN
(Homo
sapiens)		4 / 7
GLU A  63
ILE A  66
TYR A 159
VAL A 103
1.42A21.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6iex MHC CLASS I ANTIGEN
(Homo
sapiens)		4 / 6
GLU A  63
ILE A  66
TYR A 159
VAL A 103
1.36A21.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6iex MHC CLASS I ANTIGEN
(Homo
sapiens)		4 / 7
GLU A  63
ILE A  66
TYR A 159
VAL A 103
1.34A21.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6jyt HELICASE
(SARSr-CoV)		4 / 7
GLU A 420
ILE A 121
HIS A 554
PHE A 422
1.68A18.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6jyt HELICASE
(SARSr-CoV)		5 / 12
ASN B 388
GLU B 244
GLU B 128
TYR B 277
VAL B 371
1.53A18.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.73A20.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 106
TYR A 182
HIS A 164
PHE A 134
1.73A20.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 178
PHE A 103
HIS A  80
VAL A  91
1.47A20.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.58A20.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.69A20.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.70A20.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 6
GLU A 178
PHE A 103
HIS A  80
VAL A  91
1.65A20.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 6
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.72A20.88
None
None
ELL  D   3 (-4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.61A20.88
None
None
ELL  D   3 (-4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 178
TYR A 101
VAL A  18
PHE A 159
1.73A20.88
None
None
DMS  A 403 ( 4.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.61A20.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6lzg ACE2
(Homo
sapiens)		5 / 12
VAL A 581
GLU A 231
ILE A 223
TYR A 454
VAL A 447
1.61A16.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m0j SPIKE RECEPTOR
BINDING DOMAIN
(SARS-CoV-2)		4 / 6
GLU E 516
PHE E 515
TYR E 396
VAL E 341
1.61A21.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 178
PHE A 103
HIS A  80
VAL A  91
1.47A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.57A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 178
TYR A 101
VAL A  18
PHE A 159
1.72A20.82
None
None
DMS  A 401 ( 4.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 106
TYR A 182
HIS A 164
PHE A 134
1.76A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.61A20.82
None
None
ELL  D   3 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 6
GLU A 178
PHE A 103
HIS A  80
VAL A  91
1.66A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 6
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.73A20.82
None
None
ELL  D   3 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m17 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		4 / 7
ILE C 132
TYR C 128
VAL C 585
PHE C 473
1.68A18.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m17 ACE2
(Homo
sapiens)		4 / 7
GLU D 430
ILE D 291
HIS D 373
PHE D 438
1.54A16.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_F_ZPCF1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m18 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
GLU A 437
PHE A 289
TYR A 292
MET A  42
GLU A  28
1.68A18.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m18 ACE2
(Homo
sapiens)		4 / 7
TYR B 199
VAL B 184
ASN B 188
GLU B 457
1.52A16.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
PHE D 159
TYR D 101
VAL D 157
ILE D 152
1.75A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
ILE D 200
PHE D 291
HIS D 172
VAL D 125
1.60A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE C 159
TYR C 101
VAL C 157
ILE C 152
1.78A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 6
ILE D 200
PHE D 291
HIS D 172
VAL D 125
1.73A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
ILE C 106
TYR C 182
HIS C 164
PHE C 134
1.74A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
PHE B 159
TYR B 101
VAL B 157
ILE B 152
1.70A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE B 159
TYR B 101
VAL B 157
ILE B 152
1.58A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE C 140
TYR C 118
MET C  17
ASN C  28
1.72A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.67A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.70A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE D 140
TYR D 118
MET D  17
ASN D  28
1.69A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE D 159
TYR D 101
VAL D 157
ILE D 152
1.80A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
ILE C 200
PHE C 291
HIS C 172
VAL C 125
1.60A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.58A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
PHE C 159
TYR C 101
VAL C 157
ILE C 152
1.76A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
PHE B 159
TYR B 101
VAL B 157
ILE B 152
1.65A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE B 159
TYR B 101
VAL B 157
ILE B 152
1.71A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.71A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 106
TYR A 182
HIS A 164
PHE A 134
1.77A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.65A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE C 159
TYR C 101
VAL C 157
ILE C 152
1.68A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE D 159
TYR D 101
VAL D 157
ILE D 152
1.76A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.56A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
GLU B 288
GLU B 290
PHE B 291
VAL B 125
1.69A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE D 159
TYR D 101
VAL D 157
ILE D 152
1.67A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.66A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
PHE D 159
TYR D 101
VAL D 157
ILE D 152
1.79A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE B 159
TYR B 101
VAL B 157
ILE B 152
1.70A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE B 159
TYR B 101
VAL B 157
ILE B 152
1.67A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
GLU B 288
GLU B 290
PHE B 291
VAL B 125
1.65A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
ILE B 200
PHE B 291
HIS B 172
VAL B 125
1.56A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
ILE D 106
TYR D 182
HIS D 164
PHE D 134
1.73A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
ILE B 106
TYR B 182
HIS B 164
PHE B 134
1.77A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE D 159
TYR D 101
VAL D 157
ILE D 152
1.80A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.72A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 106
TYR A 182
HIS A 164
PHE A 134
1.78A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.67A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.73A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.59A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.72A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.67A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.69A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 7
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.51A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		5 / 12
ILE A 632
ASN A 628
GLU A 665
TYR A 346
HIS A 347
1.73A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 6
GLU A 136
TYR A 163
VAL A 174
PHE A 134
1.55A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.76A19.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
TYR A 915
MET A 906
ASN A 911
GLU A 919
1.55A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.75A19.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP8
(SARS-CoV-2)		4 / 7
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.73A19.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
TYR A 915
MET A 906
ASN A 911
GLU A 919
1.74A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
VAL A 587
MET A 755
ILE A 757
1.57A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_B_ZPCB1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		5 / 12
ILE A 632
ASN A 628
GLU A 665
TYR A 346
HIS A 347
1.69A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP8
(SARS-CoV-2)		4 / 7
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.77A19.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.68A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		5 / 7
PHE A 348
VAL A 535
ILE A 536
ASN A 657
GLU A 350
1.60A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 7
GLU A 136
TYR A 163
VAL A 174
PHE A 134
1.57A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		5 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
GLU A 350
1.69A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.75A19.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		5 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
GLU A 350
1.64A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 7
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.64A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.80A19.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
VAL A 587
MET A 755
ILE A 757
1.58A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_F_ZPCF1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		5 / 12
GLU A 665
TYR A 346
HIS A 347
ILE A 632
ASN A 628
1.66A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		5 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
GLU A 350
1.67A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 6
GLU C 755
ILE C 752
HIS C1040
VAL C1042
1.38A13.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
GLU C 755
ILE C 752
HIS C1040
VAL C1042
1.42A13.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
GLU C 755
ILE C 752
HIS C1040
VAL C1042
1.35A13.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6nur NSP12
(SARSr-CoV)		5 / 12
ILE A 632
ASN A 628
GLU A 665
TYR A 346
HIS A 347
1.67A14.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6nur NSP12
(SARSr-CoV)		4 / 6
GLU A 136
TYR A 163
VAL A 174
PHE A 134
1.59A14.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6nur NSP12
(SARSr-CoV)		4 / 7
GLU A 744
PHE A 745
TYR A 719
VAL A 609
1.32A14.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_B_ZPCB1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6nur NSP12
(SARSr-CoV)		5 / 12
ILE A 632
ASN A 628
GLU A 665
TYR A 346
HIS A 347
1.63A14.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6nus NSP12
(SARSr-CoV)		4 / 7
GLU A 136
TYR A 163
VAL A 174
PHE A 134
1.64A14.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
GLU C 918
HIS B1083
VAL B1104
PHE B1121
1.67A14.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vw1 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR E 453
VAL E 350
ARG E 454
ASN E 422
1.53A20.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vw1 ACE2
(Homo
sapiens)		4 / 7
GLU A 435
GLU A 430
HIS A 417
PHE A 428
1.60A16.97
None
NAG  B 711 (-3.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vww URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 6
ILE B  72
PHE B 123
TYR B 179
VAL B 149
1.51A20.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vxs NSP3
(SARS-CoV-2)		4 / 7
ILE B  69
TYR A  68
HIS A  94
VAL A  63
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vxs NSP3
(SARS-CoV-2)		4 / 7
ILE B  69
TYR A  68
HIS A  94
VAL A  63
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vxs NSP3
(SARS-CoV-2)		4 / 7
ILE B  69
TYR A  68
HIS A  94
VAL A  63
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vxs NSP3
(SARS-CoV-2)		4 / 6
ILE B  69
TYR A  68
HIS A  94
VAL A  63
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
ILE B 896
PHE B 898
TYR B 904
VAL B 911
1.40A13.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
ILE B 896
PHE B 898
TYR B 904
VAL B 911
1.46A13.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE B 898
ILE B 931
ASN B 928
ILE A1130
VAL B 722
1.57A13.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
ILE B 896
PHE B 898
TYR B 904
VAL B 911
1.48A13.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE C 898
ILE C 931
ASN C 928
ILE B1130
VAL C 722
1.59A13.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
ILE C 896
PHE C 898
TYR C 904
VAL C 911
1.42A13.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
GLU B 261
HIS B 235
VAL B 295
PHE B 264
1.43A20.44
None
CIT  B 408 (-4.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
PHE A 233
TYR A 231
VAL A 304
GLU A 234
1.48A20.44
None
EDO  A 408 (-4.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
PHE C 490
ARG C 454
ILE C 468
GLU C 484
1.36A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 8
PHE C 490
ARG C 454
ILE C 468
GLU C 484
1.46A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
GLU C 516
PHE C 515
TYR C 396
VAL C 341
1.78A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 6
GLU C 516
PHE C 515
TYR C 396
VAL C 341
1.76A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
GLU C 516
PHE C 515
TYR C 396
VAL C 341
1.76A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
PHE C 490
ARG C 454
ILE C 468
GLU C 484
1.46A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 8
PHE C 490
ARG C 454
ILE C 468
GLU C 484
1.46A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 8
PHE C 490
ARG C 454
ILE C 468
GLU C 484
1.44A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 8
PHE C 490
ARG C 454
ILE C 468
GLU C 484
1.44A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.63A
None
None
X77  A 401 ( 4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.69A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.70A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 6
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.73A
None
None
X77  A 401 ( 4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.74A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.61A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.75A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.74A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		4 / 8
PHE A6985
TYR A7009
VAL A6965
ILE A6967
1.64A17.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		5 / 12
VAL A7087
ILE A7088
ASN A6920
GLU A7082
VAL A6894
1.70A17.83
None
None
FMT  A7106 ( 4.0A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		4 / 8
PHE A6985
TYR A7009
VAL A6965
ILE A6951
1.80A17.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		4 / 7
PHE C6985
TYR C7009
VAL C6965
ILE C6967
1.59A17.83
None
NA  C7103 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		5 / 12
VAL A7086
ILE A7088
ASN A6920
GLU A7082
VAL A6894
1.79A17.83
None
None
FMT  A7106 ( 4.0A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		4 / 7
PHE C6985
TYR C7009
VAL C6965
ILE C6951
1.74A17.83
None
NA  C7103 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		4 / 8
PHE C6985
TYR C7009
VAL C6965
ILE C6967
1.61A17.83
None
NA  C7103 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		4 / 8
PHE C6985
TYR C7009
VAL C6965
ILE C6951
1.72A17.83
None
NA  C7103 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		4 / 7
PHE A6985
TYR A7009
VAL A6965
ILE A6967
1.61A17.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		4 / 8
PHE A6985
TYR A7009
VAL A6965
ILE A6967
1.63A17.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		5 / 12
VAL C7087
ILE C7088
ASN C6920
GLU C7082
VAL C6894
1.69A17.83
None
None
FMT  C7106 ( 4.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w75 NSP16
(SARS-CoV-2)		4 / 8
PHE C6985
TYR C7009
VAL C6965
ILE C6967
1.62A17.83
None
NA  C7103 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE B  55
VAL B   7
MET B  23
ILE B   5
1.62A16.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE B  55
VAL B   7
MET B  23
ILE B   5
1.67A16.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE C  55
VAL C   7
MET C  23
ILE C   5
1.77A16.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE B  55
VAL B   7
MET B  23
ILE B   5
1.69A16.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE B  55
VAL B   7
MET B  23
ILE B   5
1.69A16.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 7
GLU B 161
GLU B 167
TYR B 171
HIS B 175
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE C  55
VAL C   7
MET C  23
ILE C   5
1.72A16.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE C  55
VAL C   7
MET C  23
ILE C   5
1.75A16.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
PHE C  55
VAL C   7
MET C  23
ILE C   5
1.78A16.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR F 268
VAL F 270
ILE F 292
ASN F 269
1.64A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR E 268
VAL E 270
ILE E 292
ASN E 269
1.63A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR B 268
VAL B 270
ILE B 292
ASN B 269
1.66A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR A 268
VAL A 270
ILE A 292
ASN A 269
1.69A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR C 268
VAL C 270
ILE C 292
ASN C 269
1.63A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR A 268
VAL A 270
ILE A 292
ASN A 269
1.62A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR A 268
VAL A 270
ILE A 292
ASN A 269
1.61A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR F 268
VAL F 270
ILE F 292
ASN F 269
1.61A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR A 268
VAL A 270
ILE A 292
ASN A 269
1.64A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR B 268
VAL B 270
ILE B 292
ASN B 269
1.63A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
ILE A 292
HIS A 300
VAL A 350
PHE A 286
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR D 268
VAL D 270
ILE D 292
ASN D 269
1.65A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR E 268
VAL E 270
ILE E 292
ASN E 269
1.66A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR D 268
VAL D 270
ILE D 292
ASN D 269
1.69A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR E 268
VAL E 270
ILE E 292
ASN E 269
1.60A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR F 268
VAL F 270
ILE F 292
ASN F 269
1.61A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR D 268
VAL D 270
ILE D 292
ASN D 269
1.65A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR B 268
VAL B 270
ILE B 292
ASN B 269
1.67A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR E 268
VAL E 270
ILE E 292
ASN E 269
1.61A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR B 268
VAL B 270
ILE B 292
ASN B 269
1.71A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR A 268
VAL A 270
ILE A 292
ASN A 269
1.66A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR F 268
VAL F 270
ILE F 292
ASN F 269
1.66A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR C 268
VAL C 270
ILE C 292
ASN C 269
1.69A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
ILE C 292
HIS C 300
VAL C 350
PHE C 286
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR B 268
VAL B 270
ILE B 292
ASN B 269
1.68A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR F 268
VAL F 270
ILE F 292
ASN F 269
1.69A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR C 268
VAL C 270
ILE C 292
ASN C 269
1.61A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR A 268
VAL A 270
ILE A 292
ASN A 269
1.64A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR E 268
VAL E 270
ILE E 292
ASN E 269
1.69A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR C 268
VAL C 270
ILE C 292
ASN C 269
1.64A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR E 268
VAL E 270
ILE E 292
ASN E 269
1.64A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR D 268
VAL D 270
ILE D 292
ASN D 269
1.62A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
TYR F 268
VAL F 270
ILE F 292
ASN F 269
1.64A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR C 268
VAL C 270
ILE C 292
ASN C 269
1.66A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
TYR D 268
VAL D 270
ILE D 292
ASN D 269
1.67A16.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
PHE C6985
TYR C7009
VAL C6965
ILE C6967
1.61A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
PHE C6985
TYR C7009
VAL C6965
ILE C6967
1.63A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
PHE A6985
TYR A7009
VAL A6965
ILE A6967
1.63A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
VAL A7087
ILE A7088
ASN A6920
GLU A7082
VAL A6894
1.70A21.93
None
None
FMT  A7106 (-3.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
PHE A6985
TYR A7009
VAL A6965
ILE A6967
1.61A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
PHE C6985
TYR C7009
VAL C6965
ILE C6951
1.74A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
PHE C6985
TYR C7009
VAL C6965
ILE C6951
1.72A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
PHE C6985
TYR C7009
VAL C6965
ILE C6967
1.64A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
VAL C7087
ILE C7088
ASN C6920
GLU C7082
VAL C6894
1.70A21.93
None
None
FMT  C7103 (-4.0A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
PHE A6985
TYR A7009
VAL A6965
ILE A6951
1.79A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
PHE A6985
TYR A7009
VAL A6965
ILE A6967
1.64A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
ILE D 157
TYR D 112
HIS D 145
PHE D 110
1.77A
None
None
ZN  D 202 (-3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
ILE B 157
TYR B 112
HIS B 145
PHE B 110
1.75A
None
None
ZN  B 202 (-3.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
ILE C 157
TYR C 112
HIS C 145
PHE C 110
1.74A
None
None
ZN  C 201 (-3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		4 / 8
PHE A6985
TYR A7009
VAL A6965
ILE A6951
1.80A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		4 / 8
PHE A6985
TYR A7009
VAL A6965
ILE A6967
1.64A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		5 / 12
VAL C7086
ILE C7088
ASN C6920
GLU C7082
VAL C6894
1.80A21.93
None
None
FMT  C7106 ( 4.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		5 / 12
VAL C7087
ILE C7088
ASN C6920
GLU C7082
VAL C6894
1.66A21.93
None
None
FMT  C7106 ( 4.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		5 / 12
VAL A7086
ILE A7088
ASN A6920
GLU A7082
VAL A6894
1.77A21.93
None
None
FMT  A7109 ( 3.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		4 / 7
PHE C6985
TYR C7009
VAL C6965
ILE C6967
1.61A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		4 / 8
PHE C6985
TYR C7009
VAL C6965
ILE C6967
1.62A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		4 / 7
PHE C6985
TYR C7009
VAL C6965
ILE C6951
1.74A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		4 / 8
PHE C6985
TYR C7009
VAL C6965
ILE C6951
1.73A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		4 / 7
PHE A6985
TYR A7009
VAL A6965
ILE A6967
1.62A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		5 / 12
VAL A7087
ILE A7088
ASN A6920
GLU A7082
VAL A6894
1.67A21.93
None
None
FMT  A7109 ( 3.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		4 / 8
PHE C6985
TYR C7009
VAL C6965
ILE C6967
1.63A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wkq NSP16
(SARS-CoV-2)		4 / 8
PHE A6985
TYR A7009
VAL A6965
ILE A6967
1.64A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
GLU A 261
HIS A 235
VAL A 295
PHE A 264
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
ILE A 223
TYR A 238
VAL A 295
PHE A 214
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
PHE A 233
TYR A 231
VAL A 304
GLU A 234
1.48A21.54
None
SO4  A 410 (-3.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 6
GLU A  42
PHE A  44
TYR A  33
VAL A  23
1.75A21.54
None
TRS  A 402 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
GLU A  42
PHE A  44
TYR A  33
VAL A  23
1.74A
None
TRS  A 402 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
PHE B 233
TYR B 231
VAL B 304
GLU B 234
1.48A21.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
GLU A  42
PHE A  44
TYR A  33
VAL A  23
1.63A
None
TRS  A 402 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
GLU B  42
PHE B  44
TYR B  33
VAL B  23
1.63A
EDO  B 411 (-4.9A)
TRS  B 402 (-4.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 6
ILE A  72
PHE A 123
TYR A 179
VAL A 149
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
PHE B 233
TYR B 231
VAL B 304
GLU B 234
1.51A21.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
GLU B  42
PHE B  44
TYR B  33
VAL B  23
1.74A
EDO  B 411 (-4.9A)
TRS  B 402 (-4.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 6
GLU B  42
PHE B  44
TYR B  33
VAL B  23
1.75A21.54
EDO  B 411 (-4.9A)
TRS  B 402 (-4.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
PHE A 233
TYR A 231
VAL A 304
GLU A 234
1.51A21.54
None
SO4  A 410 (-3.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.72A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.72A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.73A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
ILE A 106
TYR A 182
HIS A 164
PHE A 134
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.60A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.68A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.69A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
GLU A 178
PHE A 103
HIS A  80
VAL A  91
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL C 155
ILE C  18
ASN C  20
GLU B 120
1.51A23.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL C 155
ILE C  18
ASN C  20
GLU B 120
1.47A23.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
GLU B 120
PHE C 156
HIS C  45
VAL C  35
1.78A
None
APR  C 201 (-4.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
GLU D 120
PHE A 156
HIS A  45
VAL A  35
1.79A
APR  A 201 ( 4.7A)
APR  A 201 (-4.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL A 155
ILE A  18
ASN A  20
GLU D 120
1.57A23.11
None
None
None
APR  A 201 ( 4.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
VAL C 155
ILE C  18
ASN C  20
GLU B 120
1.53A23.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
GLU D 120
PHE A 156
HIS A  45
VAL A  35
1.74A
APR  A 201 ( 4.7A)
APR  A 201 (-4.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
VAL C 155
ILE C  18
ASN C  20
GLU B 120
1.58A23.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL A 155
ILE A  18
ASN A  20
GLU D 120
1.56A23.11
None
None
None
APR  A 201 ( 4.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL C 155
ILE C  18
ASN C  20
GLU B 120
1.51A23.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL C 155
ILE C  18
ASN C  20
GLU B 120
1.52A23.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL A 155
ILE A  18
ASN A  20
GLU D 120
1.54A23.11
None
None
None
APR  A 201 ( 4.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
GLU D 120
PHE A 156
HIS A  45
VAL A  35
1.64A
APR  A 201 ( 4.7A)
APR  A 201 (-4.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
VAL A 155
ILE A  18
ASN A  20
GLU D 120
1.57A23.11
None
None
None
APR  A 201 ( 4.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.70A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
ILE A 106
TYR A 182
HIS A 164
PHE A 134
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.75A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.74A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.75A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.62A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.72A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6y2f REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
GLU A 178
PHE A 103
HIS A  80
VAL A  91
1.54A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.67A20.07
None
DMS  A 407 (-3.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.58A20.07
None
DMS  A 407 (-3.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.67A20.07
None
None
DMS  A 405 ( 4.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.65A20.07
None
DMS  A 407 (-3.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.70A20.07
None
DMS  A 407 (-3.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR A 396
VAL A 512
ILE A 410
GLU A 516
1.62A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
TYR A 396
VAL A 512
ILE A 410
GLU A 516
1.55A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
GLU A 516
PHE A 429
TYR A 396
VAL A 341
1.67A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE E 490
ARG E 454
ILE E 468
GLU E 484
1.63A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR A 396
VAL A 512
ILE A 410
GLU A 516
1.53A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
GLU A 516
PHE A 429
TYR A 396
VAL A 341
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
PHE E 490
ARG E 454
ILE E 468
GLU E 484
1.64A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE A 490
ARG A 454
ILE A 468
GLU A 484
1.62A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
TYR E 508
VAL E 510
ILE E 434
GLU E 406
1.72A22.74
DMS  E 902 (-4.0A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
GLU A 516
PHE A 429
TYR A 396
VAL A 341
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
GLU E 516
PHE E 515
TYR E 396
VAL E 341
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE E 490
ARG E 454
ILE E 468
GLU E 484
1.54A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR A 508
VAL A 510
ILE A 434
GLU A 406
1.79A22.74
DMS  A 903 (-3.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR E 508
VAL E 510
ILE E 434
GLU E 406
1.78A22.74
DMS  E 902 (-4.0A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
GLU E 516
PHE E 515
TYR E 396
VAL E 341
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
TYR A 508
VAL A 510
ILE A 434
GLU A 406
1.72A22.74
DMS  A 903 (-3.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
GLU E 516
PHE E 515
TYR E 396
VAL E 341
1.62A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR E 508
VAL E 510
ILE E 434
GLU E 406
1.73A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE E 490
ARG E 454
ILE E 468
GLU E 484
1.67A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
GLU E 516
PHE E 515
TYR E 396
VAL E 341
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
GLU E 516
PHE E 515
TYR E 396
VAL E 341
1.57A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE E 490
ARG E 454
ILE E 468
GLU E 484
1.57A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
TYR E 508
VAL E 510
ILE E 434
GLU E 406
1.67A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
GLU E 516
PHE E 515
TYR E 396
VAL E 341
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
PHE E 490
ARG E 454
ILE E 468
GLU E 484
1.49A22.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.59A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.67A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.66A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.72A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.71A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.71A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
GLU E 516
PHE E 515
TYR E 396
VAL E 341
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
GLU A 516
PHE A 515
TYR A 396
VAL A 341
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
TYR A 508
VAL A 510
ILE A 434
GLU A 406
1.72A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE A 490
ARG A 454
ILE A 468
GLU A 484
1.62A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
PHE E 490
ARG E 454
ILE E 468
GLU E 484
1.64A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR E 508
VAL E 510
ILE E 434
GLU E 406
1.79A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
GLU E 516
PHE E 515
TYR E 396
VAL E 341
1.61A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
GLU E 516
PHE E 515
TYR E 396
VAL E 341
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
PHE A 490
ARG A 454
ILE A 468
GLU A 484
1.63A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE A 490
ARG A 454
ILE A 468
GLU A 484
1.53A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
TYR E 508
VAL E 510
ILE E 434
GLU E 406
1.72A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
GLU A 516
PHE A 515
TYR A 396
VAL A 341
1.62A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE E 490
ARG E 454
ILE E 468
GLU E 484
1.63A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
TYR A 508
VAL A 510
ILE A 434
GLU A 406
1.79A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PHE E 490
ARG E 454
ILE E 468
GLU E 484
1.54A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
GLU A 516
PHE A 515
TYR A 396
VAL A 341
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.68A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.70A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.75A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.61A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.73A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.62A
PEG  A 405 (-4.1A)
CL  A 406 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.73A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.61A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 106
TYR A 182
HIS A 164
PHE A 134
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.69A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.73A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.61A
None
None
PJE  C   5 (-4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.70A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 6
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.72A
None
None
PJE  C   5 (-4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
PHE A 219
TYR A 217
VAL A  96
GLU A  83
1.71A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 6
GLU A  58
ILE A  66
PHE A  70
VAL A  96
1.26A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 7
GLU A  58
ILE A  66
PHE A  70
VAL A  96
1.23A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		5 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
GLU A 350
1.70A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.78A19.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		5 / 7
PHE A 348
VAL A 535
ILE A 536
ASN A 657
GLU A 350
1.66A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 7
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.65A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.64A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.77A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP8
(SARS-CoV-2)		4 / 7
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.76A19.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 7
PHE A 219
TYR A 217
VAL A  96
GLU A  83
1.68A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 7
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.61A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 7
GLU A 136
TYR A 163
VAL A 174
PHE A 134
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 7
GLU A  58
ILE A  66
PHE A  70
VAL A  96
1.21A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
PHE A 219
TYR A 217
VAL A  96
GLU A  83
1.70A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.79A19.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
PHE A 219
TYR A 217
VAL A  96
GLU A  83
1.68A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.78A19.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.65A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.61A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 7
PHE A 219
TYR A 217
VAL A  96
GLU A  83
1.70A15.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 178
TYR A 101
VAL A  18
PHE A 159
1.73A
None
None
DMS  A 403 ( 4.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.73A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 288
GLU A 290
PHE A 291
VAL A 125
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 6
GLU A 178
PHE A 103
HIS A  80
VAL A  91
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.61A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 8
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.70A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 6
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.69A
None
None
DMS  A 402 (-4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 7
GLU A 178
PHE A 103
HIS A  80
VAL A  91
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 7
PHE A 159
TYR A 101
VAL A 157
ILE A 152
1.68A20.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 200
PHE A 291
HIS A 172
VAL A 125
1.58A
None
None
DMS  A 402 (-4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 7
ILE A 106
TYR A 182
HIS A 164
PHE A 134
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.52A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.64A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.64A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.79A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP8
(SARS-CoV-2)		4 / 7
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.77A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.74A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.76A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.77A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 6
GLU A 136
TYR A 163
VAL A 174
PHE A 134
1.60A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
PHE A 348
VAL A 535
ILE A 536
ASN A 657
GLU A 350
1.63A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
VAL A 587
MET A 755
ILE A 757
1.59A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.64A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.64A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
TYR A 479
VAL A 587
ILE A 589
1.79A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
VAL A 587
MET A 755
ILE A 757
1.59A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
VAL A 587
MET A 755
ILE A 757
1.64A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
TYR A 479
VAL A 587
ILE A 589
1.78A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
PHE A 480
TYR A 479
VAL A 587
ILE A 589
1.76A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
GLU A 278
GLU A 277
HIS A 295
VAL A 354
1.71A
None
None
ZN  A1001 (-3.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
VAL A 587
MET A 755
ILE A 757
1.61A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		5 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
GLU A 350
1.64A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
GLU A 278
GLU A 277
HIS A 295
VAL A 354
1.66A
None
None
ZN  A1001 (-3.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		5 / 7
PHE A 348
VAL A 535
ILE A 536
ASN A 657
GLU A 350
1.60A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
TYR A 479
VAL A 587
ILE A 589
1.71A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.48A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP8
(SARS-CoV-2)		4 / 7
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.73A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.49A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 6
GLU A 277
PHE A 321
HIS A 295
VAL A 354
1.80A15.53
None
None
ZN  A1001 (-3.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
GLU A 278
GLU A 277
HIS A 295
VAL A 354
1.69A
None
None
ZN  A1001 (-3.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.66A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.74A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP8
(SARS-CoV-2)		4 / 7
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.78A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
VAL A 587
MET A 755
ILE A 757
1.58A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.77A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
VAL A 587
MET A 755
ILE A 757
1.57A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
TYR A 479
VAL A 587
ILE A 589
1.78A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
VAL A 587
MET A 755
ILE A 757
1.56A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
GLU A 278
GLU A 277
HIS A 295
VAL A 354
1.77A
None
None
ZN  A1001 (-3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.62A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
GLU A 278
GLU A 277
HIS A 295
VAL A 354
1.79A
None
None
ZN  A1001 (-3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
GLU A 278
GLU A 277
HIS A 295
VAL A 354
1.71A
None
None
ZN  A1001 (-3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_C_ZPCC1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
PHE A 348
VAL A 535
ILE A 536
ASN A 657
GLU A 350
1.69A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.63A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.60A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
VAL A 587
MET A 755
ILE A 757
1.61A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.54A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.75A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		5 / 7
PHE A 348
VAL A 535
ILE A 536
ASN A 657
GLU A 350
1.66A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
GLU A 350
1.59A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP8
(SARS-CoV-2)		4 / 7
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.74A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
PHE A 441
VAL A 844
ILE A 847
ASN A 414
1.73A15.53
None
None
U  P  17 ( 3.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
PHE A 480
TYR A 479
VAL A 587
ILE A 589
1.76A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.76A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP8
(SARS-CoV-2)		4 / 8
PHE B 147
TYR B 149
VAL B 130
ILE B 132
1.80A18.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
TYR A 479
VAL A 587
ILE A 589
1.78A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_D_ZPCD1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
ILE A 632
GLU A 350
PHE A 348
HIS A 295
1.68A
None
None
None
ZN  A1001 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 480
TYR A 479
VAL A 587
ILE A 589
1.70A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_E_ZPCE1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 6
GLU A 136
TYR A 163
VAL A 174
PHE A 134
1.61A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_J_ZPCJ1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.61A15.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_H_ZPCH1318_2
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
GLU A 136
TYR A 163
VAL A 174
PHE A 134
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_I_ZPCI1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
PHE A 348
VAL A 535
ILE A 536
ASN A 657
1.63A15.53
None